TKT and chronic myelogenous leukemia, BCR-ABL1 positive: TK inhibitors compete with ATP for the ATP binding site of the receptor, affecting protein phosphorylation and thus significantly reducing intracellular signaling and CML progress (Rosti et al., 2017; Jiao et al., 2018).